Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Current Quarter	$NA	Next Quarter	$NA
Current Year	$NA	Next Year	$NA
QoQ Growth	NaN%	YoY Growth	NaN%
3Y EPS CAGR	+28.2%	Target Price	$5.50
Consensus	Buy	Upside	+35.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RLMD	$4.06	-3.10%	1.62M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RLMD	$4.06	-3.1%	1.62M
3
4
5
6

RLMD

RLMD

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Relmada Therapeutics Inc. Data in Excel

Get Relmada Therapeutics Inc. Data in Excel